Foghorn Therapeutics, Inc. FHTX 深 滬
等待開盤 04-02 09:30:00 美东时间
4.90
+0.120
+2.51%
華盛通- 最 高5.05
- 今 開4.85
- 成交量 8.92万股
- 最 低 4.85
- 昨 收 4.78
- 總市值 2.88亿
- 52周最高 6.95
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 3.26
- 委 比 95.35%
- 總股本 5870.02万
- 歷史最高 28.265
- 量 比 0.64
- 振 幅 4.18%
- 歷史最低 2.70
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $13 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and maintains $13 price target.
03-10 19:27
Reported Friday, Foghorn Therapeutics Secures $50M Equity Financing, Advances Oncology Pipeline, And Extends $208.9M Cash Runway Into First Half Of 2028
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026Phase 1 dose-escalation
01-12 16:37
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.
2025-12-18 20:19
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
2025-12-05 00:56
